In vitro fertilization for women with pure tubal occlusion: the impact of short gonadotropin-releasing hormone agonist treatment.
OBJECTIVE
To evaluate the impact of a short GnRH agonist (GnRH-a) protocol on follicular and luteal characteristics and treatment outcome in women undergoing IVF for isolated pure tubal occlusion.


METHODS
A prospective randomized study.


METHODS
Eighty patients with pure tubal occlusion undergoing IVF for the first time.


METHODS
Patients in group 1 (control group) were administered hMG from day 3 of the menstrual cycle. Patients in group 2 were administered 900 micrograms/d buserelin acetate intranasally from day 1 of the menstrual cycle, followed by hMG administration from day 3. Buserelin acetate was discontinued on the day of hCG administration.


METHODS
Information collected included E2 levels and follicular growth throughout cycle, amount of hMG required for stimulation, number of oocytes retrieved, fertilization, pregnancy, and cancellation rates.


RESULTS
The short GnRH-a protocol resulted in significantly higher E2 levels and required less hMG for stimulation. However, the number of follicles aspirated, number of oocytes retrieved, fertilization rate, number of embryos transferred, pregnancy rate, and cancellation rate in both groups were comparable.


CONCLUSIONS
The findings suggest that administration of a short protocol of GnRH-a to patients with pure tubal occlusion has no obvious superiority in comparison with hMG alone, except for the lower amount of hMG required for ovarian stimulation.
Luxman
D
D
Serlin Maternity Hospital, Sourasky Medical Center, Tel Aviv, Israel.
Cohen
J R
JR
Lessing
J B
JB
Yovel
I
I
David
M P
MP
Ami
A
A
D000281:Administration, Intranasal; D002064:Buserelin / Q000008:administration & dosage* / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005184:Fallopian Tube Diseases / Q000150:complications*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy*; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies
D006063:Chorionic Gonadotropin; D004958:Estradiol; D008596:Menotropins; D002064:Buserelin